Verrica Pharmaceuticals Inc (VRCA) concluded trading on Thursday at a closing price of $0.71, with 0.48 million shares of worth about $0.34 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.96% during that period and on July 03, 2025 the price saw a gain of about 9.01%. Currently the company’s common shares owned by public are about 91.79M shares, out of which, 50.08M shares are available for trading.
Stock saw a price change of 21.32% in past 5 days and over the past one month there was a price change of 33.06%. Year-to-date (YTD), VRCA shares are showing a performance of -91.11% which increased to 0.96% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.38 but also hit the highest price of $8.98 during that period. The average intraday trading volume for Verrica Pharmaceuticals Inc shares is 420.74K. The stock is currently trading 16.15% above its 20-day simple moving average (SMA20), while that difference is up 26.47% for SMA50 and it goes to -13.66% lower than SMA200.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) currently have 91.79M outstanding shares and institutions hold larger chunk of about 31.87% of that.
The stock has a current market capitalization of $65.36M and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$1.20 in the same period. It has Quick Ratio of 1.26. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VRCA, volatility over the week remained 13.34% while standing at 11.45% over the month.
Stock’s fiscal year EPS is expected to rise by 77.72% while it is estimated to increase by 31.82% in next year. EPS is likely to grow at an annualized rate of 76.18% for next 5-years, compared to annual growth of -5.46% made by the stock over the past 5-years.
On July 25, 2023, Needham Upgrade their recommendations, while on March 22, 2023, Jefferies Initiated their ratings for the stock with a price target of $10. Stock get an Outperform rating from RBC Capital Mkts on February 13, 2023.
